Defining medication adherence in individual patients
Authors:
Open Access
- 1 July 2015
- journal article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 9, 893-897
Abstract
Background: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken. Here, we define a patient as pharmacokinetically adherent if the serum drug levels resulting from his/her pattern of medication-taking behavior remained within the therapeutic range. Methods: We used pharmacokinetic modeling to calculate serum drug levels in patients whose patterns of dosing were recorded by a medication event monitoring system. Medication event monitoring system data were from a previously published study of seven psoriasis patients prescribed 40 mg subcutaneous adalimumab at 14-day intervals for 1 year. Daily serum concentrations of adalimumab were calculated and compared with a known therapeutic threshold. Results: None of the seven patients took adalimumab precisely every 14 days. Three patients who took adalimumab at intervals of 6–26 days could be classified as pharmacokinetically adherent, because their daily adalimumab serum concentration never fell below the therapeutic threshold. The four other patients, who took adalimumab at intervals of 7–93 days, could be classified as pharmacokinetically non-adherent, because their adalimumab serum concentration fell below the therapeutic threshold on 3.5%–71.3% of days. Conclusion: Patients with varying patterns of adalimumab dosing could be classified as pharmacokinetically adherent or non-adherent according to whether or not their serum drug concentrations remained within the therapeutic range.Keywords
This publication has 15 references indexed in Scilit:
- Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritisBritish Journal of Clinical Pharmacology, 2015
- Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2014
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs DiseaseInflammatory Bowel Diseases, 2013
- Adherence to Adalimumab in Patients with Moderate to Severe PsoriasisDermatology Online Journal, 2013
- Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressantsTherapeutics and Clinical Risk Management, 2011
- Medication Compliance and Persistence: Terminology and DefinitionsValue in Health, 2008
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Modeling and simulation of adherence: Approaches and applications in therapeuticsThe AAPS Journal, 2005
- A systematic review of the associations between dose regimens and medication complianceClinical Therapeutics, 2001
- The assessment of refill compliance using pharmacy records: Methods, validity, and applicationsJournal of Clinical Epidemiology, 1997